NKTR
NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS (NKTR) has 5 SEC Form 4 filings (8 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is Chief R&D Officer Zalevsky Jonathan with 3 filings. Insiders have net sold $2.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Howard W. Robin
- Employees:61
- HQ:San Francisco, CA, US
- IPO:1994-05-03
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.0M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$2.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief R&D Officer | Sale | 5,681 | $398K | Jul 2 | SEC ↗ | |
| President & CEO | Sale | 10,000 | $603K | Jun 18 | SEC ↗ | |
| President & CEO | Sale | 10,000 | $612K | Jun 18 | SEC ↗ | |
| Chief R&D Officer | Sale | 5,538 | $336K | Jun 17 | SEC ↗ | |
ROBIN HOWARD WFirst filing | President & CEO | Sale | 444 | $29K | May 21 | SEC ↗ |
Zalevsky JonathanFirst filing | Chief R&D Officer | Sale | 199 | $13K | May 21 | SEC ↗ |
Related companies
NEKTAR THERAPEUTICS is in the Healthcare sector.